Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction.
Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction.
复制标题
阻断SARS-CoV-2刺突蛋白- ace2相互作用的单克隆抗体的鉴定和鉴定
DOI：
10.1038/s41423-021-00684-x
复制
发表时间：
2021-06
影响因子：
24.1
通讯作者：
Chen J
中科院分区：
文献类型：
--
作者：
Yuan M;Wan Y;Liu C;Li Y;Liu Z;Lin C;Chen J
2019冠状病毒病（COVID-19）是由严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）感染引起的急性肺炎。根据约翰霍普金斯大学于2021年4月6日发布的COVID-19最新统计数据，全球确诊病例为1. 3245亿例，死亡病例为287万例。由于COVID-19已成为全球性大流行病，因此迫切需要开发针对这种疾病的治疗方法，例如能够有效阻断SARS-CoV-2感染的中和抗体。在SARS-CoV-2感染宿主细胞的过程中，SARS-CoV-2的S糖蛋白在病毒进入和细胞融合中起着最关键的作用。S蛋白包括两个组分，S1和S2亚基。S1亚基在决定组织嗜性和宿主范围方面至关重要，由N-末端结构域和C-末端受体结合结构域（RBD）组成。1，2值得注意的是，S蛋白的RBD（S-RBD）支持S蛋白与宿主细胞上的血管紧张素转换酶2（ACE 2）结合，有助于SARS-CoV-2进入细胞。因此，S-RBD被广泛用于中和抗体、小分子抑制剂和疫苗的开发。4先前的研究已经报道了几种针对S-RBD的中和抗体，这些抗体是从恢复期COVID-19患者、用SARS-CoV-2 S蛋白免疫的转基因小鼠或美洲驼中鉴定的，并发现它们抑制S蛋白和ACE 2之间的相互作用。5-7除了从患者和免疫动物中分离抗体之外，工程化单克隆抗体（mAb）文库还提供了用于筛选治疗性mAb的强大工具，具有安全性、易于执行和高效的优点。8
Coronavirus disease 2019 (COVID-19) is an acute pneumonia caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the latest statistics for COVID-19 released by Johns Hopkins University on April 6, 2021, there were 132.45 million confirmed cases and 2.87 million deaths globally. Because COVID-19 has spread as a global pandemic, the development of therapeutics for this disease, such as neutralizing antibodies that can efficiently block SARS-CoV-2 infection, is urgently needed.During the infection of host cells by SARS-CoV-2, the spike (S) glycoprotein of SARS-CoV-2 plays the most crucial roles in viral entry and cell fusion. The S protein includes two components, the S1 and S2 subunits. The S1 subunit is vital in determining tissue tropism and host ranges and consists of the N-terminal domain and C-terminal receptor-binding domain (RBD). 1, 2 Of note, the RBD of the S protein (S-RBD) supports the binding of the S protein to angiotensin-converting enzyme 2 (ACE2) on host cells, contributing to cell entry by SARS-CoV-2. 3 Therefore, the S-RBD is widely used for the development of neutralizing antibodies, smallmolecule inhibitors and vaccines. 4 Previous studies have reported several neutralizing antibodies against the S-RBD that were identified from convalescent COVID-19 patients, transgenic mice or llamas immunized with the SARS-CoV-2 S protein and found to inhibit the interaction between the S protein and ACE2. 5–7 In addition to isolating antibodies from patients and immunized animals, an engineered monoclonal antibody (mAb) library provides a powerful tool for screening therapeutic mAbs, with the advantages of safety, ease of performance and high efficiency. 8
登录
查看更多内容
驴基因组为驯化和毛色选择提供了新见解
影响因子：
16.6
作者：
Wang C;Li H;Guo Y;Huang J;Sun Y;Min J;Wang J;Fang X;Zhao Z;Wang S;Zhang Y;Liu Q;Jiang Q;Wang X;Guo Y;Yang C;Wang Y;Tian F;Zhuang G;Fan Y;Gao Q;Li Y;Ju Z;Li J;Li R;Hou M;Yang G;Liu G;Liu W;Guo J;Pan S;Fan G;Zhang W;Zhang R;Yu J;Zhang X;Yin Q;Ji C;Jin Y;Yue G;Liu M;Xu J;Liu S;Jordana J;Noce A;Amills M;Wu DD;Li S;Zhou X;Zhong J
通讯作者：
Zhong J
影响因子：
24.8
作者：
Premkumar, Lakshmanane;Segovia-Chumbez, Bruno;de Silva, Aravinda M.
通讯作者：
de Silva, Aravinda M.
影响因子：
64.5
作者：
Wrapp, Daniel;De Vlieger, Dorien;McLellan, Jason S.
通讯作者：
McLellan, Jason S.
影响因子：
64.5
作者：
Walls, Alexandra C.;Park, Young-Jun;Veesler, David
通讯作者：
Veesler, David
影响因子：
64.8
作者：
Shi, Rui;Shan, Chao;Yan, Jinghua
通讯作者：
Yan, Jinghua